Advanced

Radiation immunomodulatory gene tumor therapy of rats with intracerebral glioma tumors.

Persson, Bertil R LU ; Baureus Koch, Catrin; Grafström, Gustav LU ; Ceberg, Crister LU ; Munck af Rosenschöld, Per LU ; Nittby, Henrietta LU ; Widegren, Bengt LU and Salford, Leif LU (2010) In Radiation Research 173(4). p.433-440
Abstract
Single-fraction radiation therapy with 5 or 15 Gy (60)Co gamma radiation was combined with intraperitoneal injections of syngeneic interferon gamma (IFN-gamma)-transfected cells in rats with intracerebral N29 or N32 glioma tumors at days 7, 21 and 35 after inoculation. For intracerebral N29 tumors, single-fraction radiation therapy with 5 or 15 Gy had no significant effect on the survival time. Immunization with IFN-gamma-transfected N29 cells significantly increased the survival time by 61%. Single-fraction radiation therapy with 5 Gy combined with immunization increased the survival time significantly by 87% and complete remissions by 75% while with 15 Gy the survival time increased 45% with 38% complete remissions. For intracerebral N32... (More)
Single-fraction radiation therapy with 5 or 15 Gy (60)Co gamma radiation was combined with intraperitoneal injections of syngeneic interferon gamma (IFN-gamma)-transfected cells in rats with intracerebral N29 or N32 glioma tumors at days 7, 21 and 35 after inoculation. For intracerebral N29 tumors, single-fraction radiation therapy with 5 or 15 Gy had no significant effect on the survival time. Immunization with IFN-gamma-transfected N29 cells significantly increased the survival time by 61%. Single-fraction radiation therapy with 5 Gy combined with immunization increased the survival time significantly by 87% and complete remissions by 75% while with 15 Gy the survival time increased 45% with 38% complete remissions. For intracerebral N32 tumors, single-fraction radiation therapy with 15 Gy increased the survival time significantly by 20%. Immunization by itself had no significant effect with IFN-gamma-transfected N32 cells, but combined with 15 Gy single-fraction radiation therapy it increased survival time significantly by 40%, although there were no complete remissions. Based on these findings, we suggest a new therapeutic regimen for malignant glioma using single-fraction radiation therapy with a target absorbed dose of the order of 5-10 Gy combined with clinically verified immunotherapy. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Radiation Research
volume
173
issue
4
pages
433 - 440
publisher
Radiation Research Society
external identifiers
  • WOS:000276472800005
  • PMID:20334515
  • Scopus:77950289842
ISSN
0033-7587
DOI
10.1667/RR1733.1
language
English
LU publication?
yes
id
69e957cb-0f30-4dd4-a59a-4c5c9583c911 (old id 1581720)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20334515?dopt=Abstract
date added to LUP
2010-04-08 15:47:29
date last changed
2017-01-01 07:46:41
@article{69e957cb-0f30-4dd4-a59a-4c5c9583c911,
  abstract     = {Single-fraction radiation therapy with 5 or 15 Gy (60)Co gamma radiation was combined with intraperitoneal injections of syngeneic interferon gamma (IFN-gamma)-transfected cells in rats with intracerebral N29 or N32 glioma tumors at days 7, 21 and 35 after inoculation. For intracerebral N29 tumors, single-fraction radiation therapy with 5 or 15 Gy had no significant effect on the survival time. Immunization with IFN-gamma-transfected N29 cells significantly increased the survival time by 61%. Single-fraction radiation therapy with 5 Gy combined with immunization increased the survival time significantly by 87% and complete remissions by 75% while with 15 Gy the survival time increased 45% with 38% complete remissions. For intracerebral N32 tumors, single-fraction radiation therapy with 15 Gy increased the survival time significantly by 20%. Immunization by itself had no significant effect with IFN-gamma-transfected N32 cells, but combined with 15 Gy single-fraction radiation therapy it increased survival time significantly by 40%, although there were no complete remissions. Based on these findings, we suggest a new therapeutic regimen for malignant glioma using single-fraction radiation therapy with a target absorbed dose of the order of 5-10 Gy combined with clinically verified immunotherapy.},
  author       = {Persson, Bertil R and Baureus Koch, Catrin and Grafström, Gustav and Ceberg, Crister and Munck af Rosenschöld, Per and Nittby, Henrietta and Widegren, Bengt and Salford, Leif},
  issn         = {0033-7587},
  language     = {eng},
  number       = {4},
  pages        = {433--440},
  publisher    = {Radiation Research Society},
  series       = {Radiation Research},
  title        = {Radiation immunomodulatory gene tumor therapy of rats with intracerebral glioma tumors.},
  url          = {http://dx.doi.org/10.1667/RR1733.1},
  volume       = {173},
  year         = {2010},
}